PharmD Clementi - OKYO Pharma Chief Officer
| OKYO Stock | USD 1.04 0.01 0.95% |
Executive
PharmD Clementi is Chief Officer of OKYO Pharma Ltd
| Address | 14/15 Conduit St, London, United Kingdom, W1S 2XJ |
| Phone | 44 20 7495 2379 |
| Web | https://okyopharma.com |
OKYO Pharma Management Efficiency
The company has return on total asset (ROA) of (2.9187) % which means that it has lost $2.9187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.6851) %, meaning that it created substantial loss on money invested by shareholders. OKYO Pharma's management efficiency ratios could be used to measure how well OKYO Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Equity is likely to grow to 0, while Return On Tangible Assets are likely to drop (0.01). As of the 27th of November 2024, Intangible Assets is likely to grow to about 8.9 M, while Total Assets are likely to drop about 1.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lily Fu | Virax Biolabs Group | N/A | |
| Michael JD | Foghorn Therapeutics | 59 | |
| Brian MBA | Coeptis Therapeutics | 38 | |
| Thomas Chung | Senti Biosciences | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Mike Rhee | Senti Biosciences | N/A | |
| Khullani JD | Cardio Diagnostics Holdings | 40 | |
| Anna Rivkin | Foghorn Therapeutics | N/A | |
| Mylene Touboul | Clearmind Medicine Common | N/A | |
| Pr MSW | Clearmind Medicine Common | 69 | |
| Esq JD | Cardio Diagnostics Holdings | 60 | |
| Jeffrey Cole | Cadrenal Therapeutics, Common | N/A | |
| Alfonso MD | Foghorn Therapeutics | 53 | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Adi Varon | Clearmind Medicine Common | N/A | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Douglas MBA | Unicycive Therapeutics | 62 | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| MS MD | Candel Therapeutics | 55 | |
| FACC FAHA | Cadrenal Therapeutics, Common | 66 | |
| James Wang | Virax Biolabs Group | N/A | |
Management Performance
| Return On Equity | -29.69 | ||||
| Return On Asset | -2.92 |
OKYO Pharma Leadership Team
Elected by the shareholders, the OKYO Pharma's board of directors comprises two types of representatives: OKYO Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OKYO. The board's role is to monitor OKYO Pharma's management team and ensure that shareholders' interests are well served. OKYO Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OKYO Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Beck, Founder | ||
| Keeren Shah, Chief Officer | ||
| PharmD Clementi, Chief Officer | ||
| Rajkumar Patil, Chief Officer | ||
| Gary Jacob, CEO Director |
OKYO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OKYO Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -29.69 | ||||
| Return On Asset | -2.92 | ||||
| Current Valuation | 33.7 M | ||||
| Shares Outstanding | 33.84 M | ||||
| Shares Owned By Insiders | 27.60 % | ||||
| Shares Owned By Institutions | 2.98 % | ||||
| Number Of Shares Shorted | 272 K | ||||
| Price To Book | 14.11 X | ||||
| Gross Profit | (3.6 M) | ||||
| EBITDA | (15.74 K) |
Pair Trading with OKYO Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against OKYO Stock
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.